Corcept Therapeutics (NASDAQ:CORT) Director Daniel Swisher, Jr. Sells 1,500 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director Daniel Swisher, Jr. sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $74.07, for a total value of $111,105.00. Following the completion of the transaction, the director owned 1,100 shares of the company’s stock, valued at $81,477. The trade was a 57.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Corcept Therapeutics Stock Down 1.0%

Shares of NASDAQ:CORT traded down $0.77 during midday trading on Friday, reaching $72.94. The company had a trading volume of 1,112,926 shares, compared to its average volume of 1,293,167. The business’s 50 day moving average price is $103.70 and its 200 day moving average price is $76.43. The stock has a market cap of $7.98 billion, a PE ratio of 57.43 and a beta of 0.54. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $126.38.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.84 by $0.17. The firm had revenue of $340.47 million during the quarter, compared to analysts’ expectations of $339.12 million. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The business’s quarterly revenue was up 64.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 earnings per share. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.

Institutional Trading of Corcept Therapeutics

A number of hedge funds have recently made changes to their positions in CORT. BlackRock Inc. bought a new stake in Corcept Therapeutics in the 2nd quarter valued at $1,080,964,000. Parallel Advisors LLC boosted its position in Corcept Therapeutics by 2.5% during the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock worth $160,329,000 after purchasing an additional 96,763 shares during the period. First Trust Advisors LP boosted its position in Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares during the period. Bank of New York Mellon Corp bought a new position in Corcept Therapeutics during the second quarter worth $49,185,000. Finally, Principal Financial Group Inc. increased its holdings in shares of Corcept Therapeutics by 2.5% in the first quarter. Principal Financial Group Inc. now owns 455,248 shares of the biotechnology company’s stock valued at $18,351,000 after purchasing an additional 11,156 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on CORT shares. Weiss Ratings raised shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Piper Sandler reaffirmed an “overweight” rating and set a $173.00 price target (up from $165.00) on shares of Corcept Therapeutics in a research report on Wednesday, November 4th. Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Wall Street Zen upgraded shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research report on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $139.50.

Read Our Latest Stock Analysis on CORT

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.

Read More

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.